Page last updated: 2024-12-11

carumonam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

carumonam: structure given in first source; RN given refers to (2S-(2alpha,3alpha(Z))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

carumonam : An N-sulfonated monobactam antibiotic. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6540466
CHEMBL ID1614658
CHEBI ID55486
SCHEMBL ID49606
MeSH IDM0129138

Synonyms (39)

Synonym
CHEBI:55486 ,
AC-15442
({[(1z)-1-(2-amino-1,3-thiazol-4-yl)-2-({(2s,3s)-2-[(carbamoyloxy)methyl]-4-oxo-1-sulfoazetidin-3-yl}amino)-2-oxoethylidene]amino}oxy)acetic acid
carumonamum
carumonam (inn)
87638-04-8
D07625
acetic acid, (((2-((2-(((aminocarbonyl)oxy)methyl)-4-oxo-1-sulfo-3-azetidinyl)amino)-1-(2-amino-4-thiazolyl)-2-oxoethylidene)amino)oxy)-, (2s-(2alpha,3alpha(z)))-
carumonam
ccris 1924
carumonamum [latin]
carumonam [inn:ban]
(((2-((2-(((aminocarbonyl)oxy)methyl)-4-oxo-1-sulfo-3-azetidinyl)amino)-1-(2-amino-4-thiazolyl)-2-oxoethylidene)amino)oxy)acetic acid (2s-(2alpha,3alpha(z)))-
acetic acid, (((z)-(2-(((2s,3s)-2-(((aminocarbonyl)oxy)methyl)-4-oxo-1-sulfo-3-azetidinyl)amino)-1-(2-amino-4-thiazolyl)-2-oxoethylidene)amino)oxy)-
2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2s,3s)-2-(carbamoyloxymethyl)-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxyacetic acid
A834910
2-[(z)-[2-[[(2s,3s)-2-(aminocarbonyloxymethyl)-4-oxidanylidene-1-sulfo-azetidin-3-yl]amino]-1-(2-azanyl-1,3-thiazol-4-yl)-2-oxidanylidene-ethylidene]amino]oxyethanoic acid
2-[(z)-[1-(2-amino-4-thiazolyl)-2-[[(2s,3s)-2-(carbamoyloxymethyl)-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxyacetic acid
CHEMBL1614658
AKOS015961995
486890pi06 ,
unii-486890pi06
carumonam [who-dd]
carumonam [inn]
carumonam [mi]
(z)-((((2-amino-4-thiazolyl)(((2s,3s)-2-(hydroxymethyl)-4-oxo-1-sulfo-3-azetidinyl)carbamoyl)methylene)amino)oxy)acetic acid, carbamate (ester)
ama 1080 free acid
ama-1080 free acid
acetic acid, (((2-((2-(((aminocarbonyl)oxy)methyl)-4-oxo-1-sulfo-3-azetidinyl)amino)-1-(2-amino-4-thiazolyl)-2-oxoethylidene)amino)oxy)-, (2s-(2.alpha.,3.alpha.(z)))-
SCHEMBL49606
DTXSID3048312
2-{[(z)-[(2-amino-1,3-thiazol-4-yl)({[(2s,3s)-2-[(carbamoyloxy)methyl]-4-oxo-1-sulfoazetidin-3-yl]carbamoyl})methylidene]amino]oxy}acetic acid
J-505187
2-(((e)-(1-(2-aminothiazol-4-yl)-2-(((2s,3s)-2-((carbamoyloxy)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)ac etic acid
Q5047478
DB13553
2-((((z)-1-(2-aminothiazol-4-yl)-2-(((2s,3s)-2-((carbamoyloxy)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)acetic acid
HY-121329
CS-0081447

Research Excerpts

Overview

Carumonam is a new N-sulfo-beta-lactam antibiotic active against aerobic Gram-negative bacteria. It is a monobactam with a beta-carbamyloxmethyl group at position 4.

ExcerptReferenceRelevance
"Carumonam is a new monobactam antibiotic with potent activity against gram-negative aerobes. "( Carumonam versus ceftazidime for urinary tract infections.
Cassano, K; Edelstein, H; McCabe, R; Oster, S, 1988
)
3.16
"Carumonam is a new N-sulfo-beta-lactam antibiotic active against aerobic Gram-negative bacteria. "( Clinical efficacy of carumonam.
Blakemore, PH; Drabu, YJ; Mehtar, S, 1988
)
2.04
"Carumonam is a monobactam with a beta-carbamyloxmethyl group at position 4. "( The in-vitro activity and beta-lactamase stability of carumonam.
Chin, NX; Labthavikul, P; Neu, HC, 1986
)
1.96

Pharmacokinetics

The pharmacokinetic properties of carumonam (AMA-1080, Ro 17-2301) were studied in mice, rats, rabbits, dogs, and cynomolgus monkeys and compared with those of aztreonam. The mean elimination half-life was not significantly affected by either dosage regimen or single dose versus steady state.

ExcerptReferenceRelevance
" The steady-state pharmacokinetic parameters and plasma concentration-time profiles of carumonam when adjusted for dose were similar for the three regimens."( Multiple intravenous dose pharmacokinetic study of carumonam in healthy subjects.
Banken, L; Patel, IH; Portmann, R; Soni, PP; Suter, K; Weidekamm, E, 1989
)
0.75
" Because of the large variation in the degree of renal insufficiency, calculations of the mean values for the pharmacokinetic parameters in the patient group were not generally justified with the exception of the volume of distribution (Vdss = 14."( Pharmacokinetics and dose recommendations of carumonam in renal failure.
Höffler, D; Koeppe, P; Strobel, K, 1987
)
0.53
"The pharmacokinetic properties of carumonam (AMA-1080, Ro 17-2301) were studied in mice, rats, rabbits, dogs, and cynomolgus monkeys and compared with those of aztreonam."( Comparative pharmacokinetics of carumonam and aztreonam in mice, rats, rabbits, dogs, and cynomolgus monkeys.
Fugono, T; Imada, A; Kita, Y, 1986
)
0.83
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"Our objectives were to compare the pharmacokinetics (PK) of carumonam, a monobactam, between cystic fibrosis (CF) patients and healthy volunteers and assess its pharmacodynamic profile."( Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers.
Bulitta, JB; Drusano, GL; Duffull, SB; Holzgrabe, U; Kinzig, M; Landersdorfer, CB; Sörgel, F; Stephan, U, 2009
)
0.83

Dosage Studied

Carumonam is well tolerated at both the dosage regimens. It is effective in the treatment of aerobic Gram-negative sepsis.

ExcerptRelevanceReference
" Carumonam is well tolerated at both the dosage regimens; it is effective in the treatment of aerobic Gram-negative sepsis."( Clinical efficacy of carumonam.
Blakemore, PH; Drabu, YJ; Mehtar, S, 1988
)
1.5
"The pharmacokinetics of carumonam after single and multiple intravenous administration of 1- and 2-g dosage regimens were studied in 12 young male volunteers."( Pharmacokinetics of carumonam after single and multiple 1- and 2-g dosage regimens.
Bergeron, MG; Bérubé, D; LeBel, M; Panneton, AC; Vallée, F, 1988
)
0.91
"1 micrograms/ml) 15 min after dosing and then declined with an apparent elimination half-life of 16."( Disposition of carumonam (AMA-1080/Ro 17-2301), a new N-sulfonated monocyclic beta-lactam, in rats and dogs.
Mitani, M; Naeshiro, I; Tanayama, S; Torii, H; Yoshida, K, 1986
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
monobactamMonocyclic, bacterially produced or semisynthetic beta-lactam antibiotic. It lacks the double ring construction of the traditional beta-lactam antibiotics and can be easily synthesized.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (96)

Assay IDTitleYearJournalArticle
AID1373302Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-47 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373299Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-10 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373312Antimicrobial activity against Escherichia coli expressing beta-lactamase CMY-2 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID524262Antibacterial activity against Escherichia coli NKE155 harboring deletion mutation in acrB protein and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1373285Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-2 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1373315Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-10 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373300Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-16 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373313Antimicrobial activity against Escherichia coli expressing beta-lactamase MIR-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373325Chemical stability in pH 7.4 potassium phosphate buffer assessed as half life for compound hydrolysis at 37 degC by UPLC and mass spectrometry2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID524391Antibacterial activity against Escherichia coli NKE1368 harboring deletion mutation in acrB, acrD and vector expressing mdtABC gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1373280Antimicrobial activity against wild type Escherichia coli by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373293Antimicrobial activity against Escherichia coli expressing beta-lactamase SHV-12 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373304Antimicrobial activity against Escherichia coli expressing beta-lactamase GIM-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373316Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-18 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373307Antimicrobial activity against Escherichia coli expressing beta-lactamase NDM-5 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373317Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-23 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID524266Antibacterial activity against Escherichia coli NKE128 harboring deletion mutation in acrB and tolC protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1373287Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-4 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID534382Antibacterial activity against Escherichia coli K-12 W1895 transconjugant harboring pCF243 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID534379Antibacterial activity against Citrobacter freundii KHM243 clinical isolate by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID524265Antibacterial activity against Escherichia coli NKE159 harboring deletion mutation in acrB, cpxAR protein and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID524384Antibacterial activity against Escherichia coli NKE126 harboring deletion mutation in acrB and acrD protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1373306Antimicrobial activity against Escherichia coli expressing beta-lactamase NDM-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373286Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-3 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373333Stability assessed as assessed as Escherichia coli beta-lactamase KPC-2-mediated compound hydrolysis by measuring molar enthalpy of hydrolysis at 1 mM by isothermal titration calorimetry2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1373283Antimicrobial activity against Escherichia coli expressing beta-lactamase GES-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID524260Antibacterial activity against Escherichia coli NKE96 harboring deletion mutation in acrB protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1373320Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-51 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1373284Antimicrobial activity against Escherichia coli expressing beta-lactamase IMI-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID524387Antibacterial activity against Escherichia coli NKE1365 harboring deletion mutation in acrB and mdtABC protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID524385Antibacterial activity against Escherichia coli NKE156 harboring deletion mutation in acrB protein and vector expressing acrD gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1373318Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-40 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373308Antimicrobial activity against Escherichia coli expressing beta-lactamase SPM-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID524392Antibacterial activity against Escherichia coli NKE1369 harboring deletion mutation in acrB, acrD, mdtABC protein and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1373290Antimicrobial activity against Escherichia coli expressing beta-lactamase PER-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373301Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-24 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID524388Antibacterial activity against Escherichia coli NKE1366 harboring deletion mutation in acrB and vector expressing mdtABC gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1373322Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-160 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373298Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1373291Antimicrobial activity against Escherichia coli expressing beta-lactamase PER-2 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID524261Antibacterial activity against Escherichia coli NKE154 harboring vector expressing acrB deletion mutant2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1373305Antimicrobial activity against Escherichia coli expressing beta-lactamase IMP-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID534385Antibacterial activity against Escherichia coli K-12 W1895 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID524389Antibacterial activity against Escherichia coli NKE1367 harboring deletion mutation in acrB, mdtABC protein and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1373331Stability assessed as assessed as Escherichia coli beta-lactamase SHV-12-mediated compound hydrolysis by measuring molar enthalpy of hydrolysis at 1 mM by isothermal titration calorimetry2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID524263Antibacterial activity against Escherichia coli NKE127 harboring deletion mutation in acrB and cpxAR protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1373323Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-181 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID534391Antibacterial activity against Escherichia coli JM109 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1373332Stability assessed as assessed as Escherichia coli beta-lactamase CTX-M-15-mediated compound hydrolysis by measuring molar enthalpy of hydrolysis at 1 mM by isothermal titration calorimetry2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373309Antimicrobial activity against Escherichia coli expressing beta-lactamase VIM-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1373281Antimicrobial activity against Escherichia coli expressing beta-lactamase CTXM-3 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373319Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-48 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID524383Antibacterial activity against Escherichia coli NKE161 harboring deletion mutation in acrB protein, vector expressing tolC gene and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1373324Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-225 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373310Antimicrobial activity against Escherichia coli expressing beta-lactamase AmpC by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373303Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-121 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID524390Antibacterial activity against Escherichia coli NKE1316 harboring deletion mutation in acrB, acrD and mdtABC protein2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID524264Antibacterial activity against Escherichia coli NKE158 harboring deletion mutation in acrB protein and vector expressing cpxAR gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1373296Antimicrobial activity against Escherichia coli expressing beta-lactamase VEB-4 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID534388Antibacterial activity against Escherichia coli JM109 harboring recombinant pKHM-1 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1373311Antimicrobial activity against Escherichia coli expressing beta-lactamase DHA by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373321Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-146 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373314Antimicrobial activity against Escherichia coli expressing beta-lactamase P99 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID524386Antibacterial activity against Escherichia coli NKE157 harboring deletion mutation in acrB, acrD protein and plasmid expressing nlpE gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1373294Antimicrobial activity against Escherichia coli expressing beta-lactamase SME-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373282Antimicrobial activity against Escherichia coli expressing beta-lactamase CTXM-15 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373295Antimicrobial activity against Escherichia coli expressing beta-lactamase VEB-1 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1373288Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-8 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1373289Antimicrobial activity against Escherichia coli expressing beta-lactamase NMC-A by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID1373292Antimicrobial activity against Escherichia coli expressing beta-lactamase PER-4 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
AID524382Antibacterial activity against Escherichia coli NKE160 harboring deletion mutation in acrB protein and vector expressing tolC gene2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
AID1373297Antimicrobial activity against Escherichia coli expressing beta-lactamase VEB-7 by CLSI broth microdilution method2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (85)

TimeframeStudies, This Drug (%)All Drugs %
pre-199066 (77.65)18.7374
1990's12 (14.12)18.2507
2000's4 (4.71)29.6817
2010's3 (3.53)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.76 (24.57)
Research Supply Index4.61 (2.92)
Research Growth Index4.01 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (12.50%)5.53%
Reviews2 (2.27%)6.00%
Case Studies1 (1.14%)4.05%
Observational0 (0.00%)0.25%
Other74 (84.09%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]